HRS-7172 / Jiangsu Hengrui Pharma - LARVOL DELTA

An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=140 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1/2 trial • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Hengrui Medicine…announced that it received notification from the National Medical Products Administration (NMPA) approving a clinical trial of HRS-7172 tablets in patients with advanced solid tumors harboring RAS mutations or amplifications. [Google translation] (iis.aastocks.com)

Trial status • Oncology • Solid Tumor

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Solid Tumor